Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

The use of (225)Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with (177)Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCRPC). In this study, we report the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosar, Florian, Krause, Jonas, Bartholomä, Mark, Maus, Stephan, Stemler, Tobias, Hierlmeier, Ina, Linxweiler, Johannes, Ezziddin, Samer, Khreish, Fadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156464/
https://www.ncbi.nlm.nih.gov/pubmed/34069003
http://dx.doi.org/10.3390/pharmaceutics13050722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156464/
https://www.ncbi.nlm.nih.gov/pubmed/34069003
http://dx.doi.org/10.3390/pharmaceutics13050722

Ejemplares similares